Navigation Links
Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Date:10/4/2007

h has advanced clinical programs that include new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well defined, growing library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please go to http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for PCP, which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2007 and in its other SEC filings and include: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidate, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to have a third party manufacture its drug candidate at a reasonable cost; (x) Immtech's ability to pro
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder and ... a scientific poster describing an innovative diagnostic procedure for ... Shedding New Light on Disease (SPEC) conference in Krakow, ... Treado,s poster entitled, "Development of in vitro Diagnostics for ... be discussed during the conference poster session on Tuesday, ...
(Date:8/19/2014)... -- Tokyo-based Atonarp Inc. announced today $8 million in ... Riverwood Ventures with participation from other co-investors.  The ... technology platform, which will enable a broad range ... & gas and healthcare industries for its initial ... with Atonarp in pursuing the commercialization of its ...
(Date:8/19/2014)... – a provider-led accelerator that puts the power of ... ­– announces Sutter Health, a not-for-profit health system in ... recent addition to the AVIA Innovator Network. ... focused helping patients navigate the healthcare system and enable ... so they work as a larger team for each ...
Breaking Medicine Technology:ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
... Md., Oct  27, 2011 Neuralstem, Inc. (NYSE Amex: ... in the ongoing safety trial to test its neuroregenerative small ... (MDD).  Phase Ia tested the drug in healthy volunteers for ... commence later this year, will test the safety and tolerability ...
... Oct. 27, 2011 Herborium Group, Inc., ... company, announced the following update today. ... stated: "These are truly exciting times for our Company. ... Bulletin Board exchange by maintaining Herborium, Current Information ...
Cached Medicine Technology:Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 2Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 3Herborium Group Shareholders Update 2Herborium Group Shareholders Update 3
(Date:8/20/2014)... This agreement will allow storageFOUNDRY ... networking, high availability cloud enablement, service, and elastic ... allowing OPEN-V to sell storageFOUNDRY’s expanding Nautilus line ... with OPEN-V on this distribution agreement of our ... channels at storageFOUNDRY. "Nautilus is a massively scalable, ...
(Date:8/19/2014)... well-known bamboo product manufacturer and retailer, has unveiled its new ... excited to reveal the new items, and it has decided ... every customer can get a discounted price, up to 30 ... , The company’s deckings are made of the finest quality, ... are perfect for a dining room, living room, kitchen, foyer, ...
(Date:8/19/2014)... Crosley Law Firm, PC has reached a confidential ... Star Bakery for an undisclosed amount. The two claimants, Pete ... of 2011, respectively. The injuries were caused by two different ... to the left hand of each man. , At the ... short-staffed, having lost 200 of its, 500 workers in connection ...
(Date:8/19/2014)... an outstanding company in the garment industry, has unveiled its ... to this, the company has also launched a big sale ... at low rates, up to 30 percent off. , ... bohemian outfits are available in many colours, including green, blush, ... quality clothes, reasonable prices and sincere service, the company has ...
(Date:8/19/2014)... the brain involved in multitasking and ways to train ... the IUGM Institut universitaire de griatrie de Montral and ... to better predict the effectiveness of this training. Cooking ... the Web, or driving while listening to a radio ... our daily lives. Unfortunately, it decreases with age, which ...
Breaking Medicine News(10 mins):Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Promotional Bamboo Deckings from Well-known Online Supplier BambooIndustry.com 2Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:Targeted brain training may help you multitask better 2
... have found out why women who have a baby when ... breast cancer. They have identified a substance produced naturally in ... pregnancy trigger the changes in the breast tissue of young ... a pill that could protect against breast cancer. ...
... franchisee for US based Medicine Shoppe International, with operations in ... list of its target for operations in the country. According ... expand its franchisee operations from the present 19 outlets to ... decided to put on hold the commencing of operations in ...
... Common childhood vaccinations, including newer ones such as those ... diabetes. The conclusion came from a look at 768 ... had juvenile diabetes. Those who had been vaccinated against ... no more likely to have developed diabetes than those ...
... hormone production may help explain why obese people who carry ... a high risk of heart disease and other health problems. ... and its complications. // ,It is no news ... heart disease and diabetes, but where these extra pounds accumulate ...
... some time that a wide range of influenza viruses circulate in ... humans. These are two subtypes of the influenza A virus known ... was reported in Hong Kong in mid-May . ,The ... six people and infect 12 others in a small but densely ...
... may not only an effective treatment for malaria, the ... be similar to the mechanism they use to ... these findings at the 50th Annual Meeting of the ... ,The compounds called disulfides, occur naturally in garlic, ...
Cached Medicine News:
... Tips are available as both regular and ... by gamma-rays for more efficient sterilization and ... specifying the date of irradiation. Sterilized Diamond ... to autoclave. SterilPack Diamond Tips are wrapped ...
This large 1000 L tip makes pipetting fragile cells, genomic DNA, and viscous samples easy. Perfect for cell culture laboratories....
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
Conducting disposable filter-tips....
Medicine Products: